Today: 21 May 2026
Intel stock price: INTC reels after outlook miss, supply crunch sets up Monday test
24 January 2026
2 mins read

Intel stock price: INTC reels after outlook miss, supply crunch sets up Monday test

New York, Jan 24, 2026, 16:19 EST — Market closed.

  • Intel shares plunged sharply after earnings, with investors zeroing in on supply constraints rather than demand.
  • Management highlighted ongoing tight supply for key chips, despite a pickup in AI-driven data-center orders.
  • Traders are now focused on whether supply constraints will loosen this quarter and if the turnaround story will stick.

Intel (INTC) shares ended Friday at $45.07, tumbling 17% after hitting a session low of $44.25 amid heavy volume. With U.S. markets closed Saturday, the stock heads into Monday’s open under pressure.

The weekend didn’t shift the fundamentals. Intel’s recent guidance sharpened a narrative investors had seen as a steady recovery, refocusing attention on execution over vision.

The key issue now is that supply bottlenecks can limit revenue, even with strong demand. That’s a tough reality for a stock that had been rallying quickly ahead of earnings and attracting more speculative investors.

Intel reported fourth-quarter revenue of $13.7 billion, down 4% year-over-year, with adjusted EPS at $0.15, in a release late Thursday. The company forecast first-quarter revenue between $11.7 billion and $12.7 billion, with non-GAAP EPS at zero. It also expects a non-GAAP gross margin around 34.5%. CEO Lip-Bu Tan said Intel is pushing “aggressively to grow supply,” while CFO David Zinsner noted supply availability should hit its lowest point in Q1 before improving in Q2 and beyond. intc.com

On the earnings call, Tan said he was “disappointed” that Intel couldn’t fully meet demand. Factories are running at capacity but still falling short on server CPUs for AI accelerator applications in data centers. Two customers are now reviewing the technical specs of Intel’s upcoming 14A manufacturing process—part of its foundry strategy aimed at contract chipmaking for external designers. Executives expect to know by year-end whether those customers will go ahead. The forecast suggests a break-even adjusted profit for Q1, compared to Wall Street’s 5 cents a share estimate, Reuters reported, citing LSEG data. Reuters

Friday’s selloff came after a January surge that pushed the stock sharply higher, leaving little margin for error. TD Cowen noted the rally was fueled more by “the dream” than by solid near-term fundamentals. Bernstein suggested Intel seemed blindsided by the server cycle. Jefferies predicts the shortage might hit bottom in March, while Oppenheimer expects constraints to ease by the second quarter. Intel also flagged a memory-chip shortage that could drag on PC demand. Reuters

The tape highlighted just how isolated Intel’s decline was. Nvidia and AMD wrapped up Friday with gains, even as broad semiconductor ETFs dipped around 1%—a modest retreat compared to Intel’s fall.

Intel submitted an SEC filing Friday, updating a resale registration linked to a warrant and shares held by the U.S. Department of Commerce. The company clarified no new securities were issued and it won’t get proceeds from any sales. Still, some investors may view the registration as a potential supply overhang.

The risk scenario is clear: if supply easing lags behind management’s timeline, the company could end up “leaving sales on the table” for longer. Margins will remain squeezed if manufacturing yields—the percentage of usable chips per wafer—don’t pick up quickly. Factor in rising component costs that push PC prices higher, and it’s easy to understand why traders have been trimming their positions.

The next key date is Monday, Jan. 26. Investors will be looking out for follow-up broker notes, updates on supply timing, and whether Intel’s stock can find footing after two days of sharp swings post-earnings.

Stock Market Today

  • Teradyne, Kulicke and Soffa, Impinj, Microchip, IPG Photonics Stocks Slide on U.S.-China Semiconductor Summit Outcome
    May 21, 2026, 2:58 AM EDT. Shares of Teradyne, Kulicke and Soffa, Impinj, Microchip Technology, and IPG Photonics dropped sharply following the U.S.-China summit, which ended without key breakthroughs on semiconductor exports. Expectations for U.S. approval of Nvidia's H200 chip shipments to China were unmet, disappointing investors. U.S. Trade Representative Jamieson Greer indicated semiconductors were not a negotiation focus, dampening near-term optimism. Despite the sell-off, IPG Photonics' stock, known for volatility, remains down significantly from its 52-week high but has gained 34.3% year-to-date. Market reactions highlight cautious sentiment amid geopolitical tensions, with analysts skeptical about swift comprehensive deals due to national security concerns.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Goldman Sachs stock slides into Fed week after CEO pay disclosure
Previous Story

Goldman Sachs stock slides into Fed week after CEO pay disclosure

Vallourec’s Delphy hydrogen storage lands Hyvolution award nod as Paris show nears
Next Story

Vallourec’s Delphy hydrogen storage lands Hyvolution award nod as Paris show nears

Go toTop